Navigation Links
Terumo To Simultaneously Evaluate Misago Self-Expanding Stent System in the United States and Japan
Date:5/12/2010

ence between FDA and MHLW-PMDA (Japan's regulatory bodies).  The learning obtained in the "proof of concept" trials will assist both regulatory bodies in streamlining the clinical trial process for faster approvals in both countries, as well as promote the idea of global trials for purposes of collecting better data.  In this pilot HBD approach, the products will be submitted for review and approval at the same time.

"I believe this approach to shorten the time for new product approvals between the U.S. and Japan is critical and exciting," said Takao Ohki, MD, Chairman and Professor, Department of Surgery, Jikei University School of Medicine, Division of Vascular Surgery, and the global principal investigator of the OSPREY trial.  "This innovative movement could dramatically solve the current device lag issue between our countries."

In the U.S., OSPREY is a single-arm, multi-center, non-randomized prospective clinical trial for the treatment of atherosclerotic stenoses and occlusions of the SFA.  In Japan, there are two arms of the study, 50 patients receiving the MISAGO Stent and 50 patients receiving percutaneous transluminal angioplasty (PTA).  

The primary endpoints of the U.S. study are:

  • Primary stent patency rate at one year as confirmed by duplex ultrasound or angiography.
  • Freedom from major adverse events within 30 days of the procedure, which would result in target lesion revascularization, amputation of the treated limb or death.

The study will include up to 350 patients, a maximum of 250 patients in up to 30 centers in the U.S. and 100 patients in Japan.  There have already been
'/>"/>

SOURCE Terumo Interventional Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
2. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
3. Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants
4. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
5. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
6. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
7. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
8. Terumo to Sponsor Presentations on Key Issues in Cardiac and Vascular Surgery at Society of Thoracic Surgeons Annual Meeting
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
11. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... NEW YORK , July 31, 2014 ... developing better, faster and affordable treatments for tuberculosis (TB), ... Senior Vice President, Market Access. Ms. Robertson joins the ... the company,s business in Sub-Saharan Africa and ... will oversee the TB Alliance,s efforts to ensure beneficial ...
Breaking Medicine Technology:Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2genae Opens Offices in London 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3
... SAN ANTONIO, July 12, 2011 Sevocity, the ... that Sevocity v11.1 has achieved full certification through ... and is a CCHIT Certified® 2011 Ambulatory EHR. ... usability rating, the highest level awarded by CCHIT. ...
... Surgical Care Affiliates (SCA), a national leader in ... and surgery departments, announced today it has entered into ... subsidiary of Suburban Hospital Healthcare System, Inc., a member ... in the Bethesda and Montgomery County areas. ...
Cached Medicine Technology:Sevocity Division of Conceptual MindWorks Inc.'s Sevocity EHR Earns CCHIT 2011 Certification 2Surgical Care Affiliates Announces Agreement With Suburban Outpatient Surgery Center 2
(Date:7/31/2014)... 31, 2014 The 2013 edition ... about chemical listings, appellate decisions, litigation and settlement ... affect compliance with California's Proposition 65. , The ... law, regulations, history and trends impacting California's Proposition ... installment of the series which adds approximately 200 ...
(Date:7/31/2014)... 2014) Women over the age of 65 face ... obesity, greater struggles against poverty and higher rates of ... the August issue of Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), outlines the ... offers practical solutions to improve their care. ...
(Date:7/31/2014)... used birth control pills containing high-dose estrogen and a ... cancer, whereas women using some other formulations did not, ... a journal of the American Association for Cancer Research. ... contraceptives [birth control pills] in the past year is ... never or former oral contraceptive use, and that this ...
(Date:7/31/2014)... 2014 Developer Jamestown, L.P., has been ... Ponce City Market project in Atlanta’s Old Fourth Ward, ... Company building into best-in-class office, housing, and retail spaces. ... experience with their construction webcam service to assess how ... a construction camera for monitoring and documentation ...
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars , opened ... Horn Road in Lake Leelanau. Joining the Northern Loop of ... the 25th winery along the trail. The winery will participate ... making its trail event debut during the Harvest Stompede on ... and Faye Mathia opened the boutique winery in the former ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2
... 28 Dr. Jeffrey Cummings, Medical,Director of The ... the prestigious Ronald and Nancy Reagan Research Award ... themselves to, discovering new,treatments and methods of care ... In his speech of acceptance at the annual ...
... finds molecule boosted cells eliminating colitis, Crohn,s symptoms , , ... by intestinal bacteria can eliminate symptoms of inflammatory bowel ... includes Crohn,s disease and ulcerative colitis. , It ... and other mammals contain about 1,000 different species of ...
... of Pennsylvania School of Medicine have shown how Argos, ... binding growth factors that promote the progression of cancer. ... new drug designs for inhibiting cancer. The study appeared ... Many types of tumors grow because of over-expression of ...
... 300-Page Book, with Foreword by FDA,s Janet Woodcock, ... WASHINGTON, May 28 Now that the Food ... the safe use of,pharmaceuticals, drug manufacturers can be ... their marketing on,existing pharmaceuticals., To help pharmaceutical ...
... DRAXIS Health Inc. ("DRAXIS"),(TSX: DAX) (NASDAQ: DRAX ) ... all of DRAXIS, common shares have been acquired by,an ... common share. As a result, DRAXIS common stock is ... on the Toronto Stock Exchange at,market close on Thursday, ...
... engineer. As a youngster, she had a fascination with ... Today, Sullivan, an assistant professor of chemical engineering at ... applying her knowledge and talents to an area critical ... drugs and gene therapies to diseased and damaged cells ...
Cached Medicine News:Health News:Gut Bacteria Fights Inflammatory Bowel Disease 2Health News:Fruit fly protein acts as decoy to capture tumor growth factors, find Penn researchers 2Health News:FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management 2Health News:DRAXIS Announces Completion of Sale to Jubilant 2Health News:DRAXIS Announces Completion of Sale to Jubilant 3Health News:DRAXIS Announces Completion of Sale to Jubilant 4Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 2Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 3
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box....
Disposable Aluminum Satin Finish E/T Stylette, Adult 16, 25/box....
Medicine Products: